BMH invests in developer of sustainable cell cultivation systems

Green Elephant Biotech closes pre-seed funding round

15-Feb-2022 - Germany

Beteiligungs-Managementgesellschaft Hessen mbH ("BMH"), the medium-sized investment and venture capital company of the State of Hesse, is investing in Green Elephant Biotech GmbH. In addition to the lead investor BMH, a consortium of industry-experienced business angels also participated in the pre-seed funding round in the total mid-six-figure range. With "CellScrew", Green Elephant Biotech has developed an innovative and patented cell cultivation system for use in the biopharmaceutical industry that is superior to products previously available on the market in terms of efficiency, flexibility and sustainability. The new funds are intended to accelerate the growth of the Giessen-based start-up as well as finance the fees for certifications and patents.

Elephant Biotech GmbH

The Green Elephant Biotech founders Felix Wollenhaupt (left), Joel Eichmann

Green Elephant Biotech, based in Giessen, is a spin-off from the Technical University of Applied Science Mittelhessen ("THM") and was founded by Joel Eichmann and Felix Wollenhaupt in December 2021. The company's core idea and vision is to produce life-saving drugs and vaccines through efficient, scalable cell cultivation and - thanks to additive manufacturing - using CO2neutral materials. The business model is based on the automated production and distribution of the proprietary, patented "CellScrew" technology in the form of "single-use" articles to biotech and pharmaceutical companies that are actively involved in the development of new vaccines or are researching cell and gene therapy treatments. Compared to a classic roller bottle, the "CellScrew" offers an enormously increased growth surface with the same volume. In an existing infrastructure, users can thus increase production many times over, align it more sustainably and save on personnel costs at the same time. The "CellScrew" technology could, for example, enable high-priced drugs, diagnostics and vaccines to be produced more cheaply in larger quantities. 

"The growing demand for adherent cell cultures requires efficient and scalable cell culture systems. With our patented solution, users can generate significant efficiencies from development to production while improving their environmental footprint. Now it is time to grow healthily as a company and establish our product in the market. Thanks to the support of experienced and excellently networked investors, we are ideally equipped to do so," explains Dr. Joel Eichmann, founder and managing director of Green Elephant Biotech. 

The funds from the current pre-seed funding round are intended to enable the expansion of the team as well as the further development of the "CellScrew" technology to commercial market maturity. Green Elephant Biotech also plans to invest in the necessary certifications. 

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...

Something is happening in the life science industry ...

This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.

See the theme worlds for related content

Topic world Cell culture technology

Cell culture technology is a central pillar in biotechnological and pharmaceutical research and development. It enables the growth and maintenance of cells under controlled laboratory conditions, providing a window into the molecular and cellular processes of life.

3 whitepaper
View topic world
Topic world Cell culture technology

Topic world Cell culture technology

Cell culture technology is a central pillar in biotechnological and pharmaceutical research and development. It enables the growth and maintenance of cells under controlled laboratory conditions, providing a window into the molecular and cellular processes of life.

3 whitepaper